Is Acromegalic Cardiomyopathy Reversible?
At a Glance
Acromegalic cardiomyopathy is often partially reversible if treated early. Normalizing growth hormone and IGF-1 levels can reduce heart thickness and improve function. However, if the condition progresses to permanent scarring or heart failure, the damage may be irreversible.
In this answer
3 sections
Yes, in many cases, acromegalic cardiomyopathy is at least partially reversible once your growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are brought back to normal. Achieving biochemical control of acromegaly can halt the progression of heart changes and often significantly improves the heart’s structure and function [1][2]. However, the extent of recovery heavily depends on how early the condition is treated, as severe or long-standing heart damage may not be fully reversible [1][3].
How Normalizing Hormones Helps Your Heart
Acromegalic cardiomyopathy usually begins with the heart muscle becoming thicker (biventricular hypertrophy) and stiffer, which affects how well the heart relaxes and fills with blood (diastolic dysfunction) [4].
When you successfully treat acromegaly—whether through surgery, medication, or radiation—and normalize your GH and IGF-1 levels, the excess growth signal affecting the heart is removed [5]. Research shows that this biochemical control leads to a decrease in the thickness of the left heart ventricle (the heart’s main pumping chamber) and an improvement in the heart’s overall structural and functional health [6][7].
For many patients, reaching and maintaining normal hormone levels effectively stops the progression of the cardiomyopathy and improves cardiac function, particularly how the heart responds to physical exercise [1][8]. These improvements do not happen overnight; your heart’s structure and function will typically recover gradually over several months to years of sustained hormone control [8].
When Is the Damage Irreversible?
While early treatment often leads to excellent improvements, there are limits to how much the heart can heal. Evidence shows that some cardiac impairments may persist even when biochemical control is successfully achieved [9].
If acromegaly goes untreated for a long time, the heart muscle may develop permanent scarring (fibrosis) [10]. Over time, a thickened, stiff heart can transition into an enlarged, weakened state (dilated cardiomyopathy), which can lead to congestive heart failure [1]. Studies indicate that once dilated cardiomyopathy and congestive heart failure have developed, the cardiac dysfunction is generally not reversible, despite subsequent achievement of biochemical control [1][3]. Additionally, structural issues like abnormalities in the heart valves often persist after treatment [11][10].
Symptoms to Watch For
Because you want to catch these issues long before they become irreversible, it’s important to monitor how you feel. Alert your doctor if you experience symptoms like unusual shortness of breath (especially when lying down or during mild exertion), persistent fatigue, or new swelling in your legs and ankles.
What This Means for Your Ongoing Care
Because the reversibility of heart issues depends so heavily on early intervention, strict control of your hormone levels is the best strategy to protect your heart and limit complications [12][13].
Your doctor will likely monitor your heart using echocardiograms (an ultrasound of the heart) to track changes in your heart’s mass and function over time [14][15]. Routine screening with these echocardiograms is designed exactly for this purpose: to detect early, reversible changes long before they progress to permanent damage.
It is also crucial to manage other heart disease risk factors. For example, high blood pressure (hypertension) significantly contributes to heart thickening in acromegaly. Effectively managing both your blood pressure and your hormone levels is essential for your long-term cardiac prognosis [16][7]. Because full reversal of structural changes is not always achieved, you may still need ongoing care from a cardiologist, especially if you have had active acromegaly for many years or if you have other risk factors like an increased BMI [11][17].
Common questions in this guide
How does treating acromegaly help the heart?
Will my heart completely return to normal after acromegaly treatment?
At what point is heart damage from acromegaly irreversible?
Why is blood pressure management important for acromegaly patients?
How will my doctor monitor my heart health?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What is my current baseline heart function, and do my recent echocardiograms show any signs of muscle thickening or stiffness?
- 2.Should I be seeing a cardiologist now to establish a baseline, or only if my echocardiogram shows abnormalities?
- 3.Are there specific blood pressure goals I should be aiming for to best protect my heart while my growth hormone levels are being managed?
- 4.How often should I have an echocardiogram or other heart imaging repeated to track any changes?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (17)
- 1
Acromegaly and Heart Failure.
Colao A, Grasso LFS, Di Somma C, Pivonello R
Heart failure clinics 2019; (15(3)):399-408 doi:10.1016/j.hfc.2019.03.001.
PMID: 31079698 - 2
Endoscopic therapy and curative effect in pituitary adenoma patients complicated by acromegalic cardiomyopathy.
Zhou H, Zha Z, Li X, et al.
Neurosurgical review 2018; (41(3)):869-875 doi:10.1007/s10143-017-0936-7.
PMID: 29238923 - 3
Acromegaly with Dilated Cardiomyopathy.
Dargad RR, Parekh JD, Dargad RR
The Journal of the Association of Physicians of India 2016; (64(6)):96-97.
PMID: 27739285 - 4
Cardiovascular Disease in Acromegaly.
Sharma MD, Nguyen AV, Brown S, Robbins RJ
Methodist DeBakey cardiovascular journal 2017; (13(2)):64-67 doi:10.14797/mdcj-13-2-64.
PMID: 28740584 - 5
Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management.
Sharma AN, Tan M, Amsterdam EA, Singh GD
Clinical cardiology 2018; (41(3)):419-425 doi:10.1002/clc.22867.
PMID: 29574794 - 6
The effect of first intervention on cardiac parameters in patients with acromegaly: a systematic review.
Huynh KA, Al-Gully J, Montero-Cabezas JM, et al.
European journal of endocrinology 2025; (192(2)):S1-S14 doi:10.1093/ejendo/lvaf009.
PMID: 39880368 - 7
Impact of Medical Therapies on Cardiovascular Risk Factors in Acromegaly.
Wekesa R, Chatterjee S, Alhiraki O, Sheikh A
Cureus 2025; (17(6)):e86106 doi:10.7759/cureus.86106.
PMID: 40672042 - 8
Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
Colao A, Cuocolo A, Marzullo P, et al.
The Journal of clinical endocrinology and metabolism 2001; (86(4)):1551-7 doi:10.1210/jcem.86.4.7376.
PMID: 11297582 - 9
The spectrum of cardiac abnormalities in patients with acromegaly: results from a case-control cardiac magnetic resonance study.
De Alcubierre D, Feola T, Cozzolino A, et al.
Pituitary 2024; (27(4)):416-427 doi:10.1007/s11102-024-01403-1.
PMID: 38847918 - 10
Cardiovascular complications of acromegaly.
Kamenický P, Maione L, Chanson P
Annales d'endocrinologie 2021; (82(3-4)):206-209 doi:10.1016/j.ando.2020.03.010.
PMID: 33168155 - 11
Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options.
Goldberg MD, Vadera N, Yandrapalli S, Frishman WH
Cardiology in review 2018; (26(6)):307-311 doi:10.1097/CRD.0000000000000215.
PMID: 29794808 - 12
Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities.
Pivonello R, Auriemma RS, Grasso LF, et al.
Pituitary 2017; (20(1)):46-62 doi:10.1007/s11102-017-0797-7.
PMID: 28224405 - 13
Combined treatment with octreotide LAR and pegvisomant in patients with pituitary gigantism: clinical evaluation and genetic screening.
Mangupli R, Rostomyan L, Castermans E, et al.
Pituitary 2016; (19(5)):507-14 doi:10.1007/s11102-016-0732-3.
PMID: 27287035 - 14
Speckle-tracking echocardiography reveals the synergistic impact of GH/IGF-1 excess and metabolic dysregulation on cardiac dysfunction in acromegaly.
Chen M, Zhang P, He W, et al.
Pituitary 2026; (29(3)).
PMID: 42213228 - 15
[Cardiovascular complications associated with acromegaly. A state-of-the-art].
Concepción-Zavaleta M, Muñoz-Moreno J, Quispe-Flores M, et al.
Archivos de cardiologia de Mexico 2022; (92(4)):513-521 doi:10.24875/ACM.21000339.
PMID: 35389604 - 16
CARDIOVASCULAR COMPLICATIONS OF ACROMEGALY.
Mizera Ł, Elbaum M, Daroszewski J, Bolanowski M
Acta endocrinologica (Bucharest, Romania : 2005) 2018; (14(3)):365-374 doi:10.4183/aeb.2018.365.
PMID: 31149285 - 17
Cardiovascular System Changes and Related Risk Factors in Acromegaly Patients: A Case-Control Study.
Guo X, Gao L, Zhang S, et al.
International journal of endocrinology 2015; (2015()):573643 doi:10.1155/2015/573643.
PMID: 26600803
This page provides information on acromegalic cardiomyopathy reversibility for educational purposes only. Always consult your endocrinologist or cardiologist for medical advice regarding your heart health.
Get notified when new evidence is published on Acromegaly.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.